Summary of the Core Content
This is the most surprising “black swan” event in the pharmaceutical industry this year: the once universally recognized “low-risk” field of lipid-lowering therapy for apolipoprotein A (Lp(a)) has encountered a major setback led by Novartis. Their heavily funded new drug, pelacarsen, significantly reduced Lp(a) levels by up to 80% in trial participants, with 98% of them reaching below the safety threshold. However, it failed to demonstrate any effect in reducing cardiovascular diseases such as myocardial infarctions and strokes. This failure has overturned decades of consensus in the medical and pharmaceutical communities, not only rendering Novartis’ billions in research and development investments worthless but also casting doubt on the approaches of other giants like Amgen and Eli Lilly pursuing similar treatments, as well as the U.S. government’s previous recommendation for universal Lp(a) screenings.
---
Detailed Analysis
1. Explaining Lp(a) Therapy to the Layperson
You’ve probably heard that high levels of “bad cholesterol” (LDL) increase the risk of heart attacks. Statins and PCSK9 inhibitors, which lower LDL, have sold for billions because the logic is straightforward: high LDL → blocked blood vessels → reduced disease incidence. Lp(a) was previously considered an even more certain risk factor for cardiovascular diseases:
It is entirely determined by genetics; no matter how much you eat a healthy diet or exercise, your Lp(a) levels remain unchanged. About 20% of people are born with a higher risk due to genetic factors, and existing lipid-lowering drugs were almost ineffective against it. Statins could even increase Lp(a) levels slightly, while the strongest PCSK9 inhibitors could only reduce it by 20%-30%, which is far from sufficient to treat the condition.
Decades of research have shown that people with high Lp(a) have a significantly higher risk of cardiovascular diseases. When Novartis’ new drug showed a 80% reduction in Lp(a) levels in phase II trials, the industry was thrilled, anticipating billions in sales. Medical guidelines recommended that all adults should have their Lp(a) checked at least once to identify this inherent risk factor.
2. How This Failure Challenges Common Beliefs
The problem wasn’t with the drug’s efficacy but with the fundamental understanding of the disease:
Novartis’ phase III trials focused on patients with extremely high Lp(a) levels. Although 98% of them had their Lp(a) levels reduced to the safety threshold, this didn’t correspond to a reduced risk of heart attacks or strokes. It’s like eliminating all the cockroaches in your home only to find no improvement in your allergy symptoms.
The failure challenges the idea that lowering Lp(a) significantly reduces cardiovascular risks. If Lp(a) is primarily genetic, reducing it by 80% should have greatly reduced the risk of disease, but the results were the same as those in the placebo group, indicating no real benefit.
3. Industry Attempts to Shift Blame
Companies like Amgen and Eli Lilly tried to downplay the failure, claiming their drugs could reduce Lp(a) by 90% in phase II trials, suggesting they might be more effective. However, this argument is flawed: Novartis’ drug already reduced Lp(a) levels by more than 50%, which is a significant improvement. Even if their drug reduced it by another 10%, it wouldn’t suddenly make it a powerful treatment.
The failure highlights that even if a drug shows some effect, the benefits are likely minimal compared to the huge investments made in the field.
4. The broader Implications
This failure shakes fundamental assumptions in the pharmaceutical industry:
If lowering Lp(a) doesn’t prevent cardiovascular diseases, does that mean our previous understanding of the causes of these diseases is incorrect? It’s possible that Lp(a) is not the primary culprit but merely a secondary factor. If there’s another genetic factor causing both increased Lp(a) and cardiovascular risks, then screening for Lp(a) becomes meaningless.
This incident serves as a reminder that no business in the pharmaceutical industry is truly “risk-free.” Even with strong evidence, the effectiveness of a drug must be proven in clinical trials before it can be widely adopted.
5. A Warning for All Industries
The failure of Lp(a) therapy highlights that no investment is completely secure in the pharmaceutical sector. The success of PCSK9 inhibitors was also based on assumptions that proved incorrect. This incident highlights the importance of rigorous clinical validation before making major investments.